Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Wellcome Trust has granted $2.8m Translation Award to Canbex Therapeutics to develop a drug for the treatment of the debilitating muscle spasms associated with multiple sclerosis (MS) and potentially other disorders.
Subscribe to our email newsletter
Canbex said the award will further support the preclinical trials of the company’s VSN series of compounds.
The company expects to initiate Phase I trial of VSN16R, company’s lead compound, in the beginning of December 2012.
Preclinical studies have shown that VSN16R treatment reduces muscle spasms in an animal model of MS spasticity, with a far lower burden of side effects than the decades-old compounds that are currently in clinical use.
Canbex CEO Stephane Mery said they are delighted that Canbex can move their lead compound VSN16R forward towards clinical trials.